Home

Minerva Neurosciences, Inc. (NERV)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Minerva Neurosciences, Inc. (NERV)

Go deeper and ask any question about NERV

Company Performance

Current Price

as of Sep 13, 2024

$2.95

P/E Ratio

N/A

Market Cap

$20.63M

Description

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Metrics

Overview

  • HQBurlington, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerNERV
  • Price$2.95+7.27%

Trading Information

  • Market Cap$20.63M
  • Float77.74%
  • Average Daily Volume (1m)14,267
  • Average Daily Volume (3m)21,698
  • EPS-$4.45

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$8.23M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$6.27M
  • EV$79.74M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
Documents